Breyanzi (lisocabtagene maraleucel)

pCPA File Number: 21939
Negotiation Status:
Under consideration for negotiation
Indication(s):
Adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma
Sponsor/Manufacturer:
Celgene Inc.
CADTH Project Number:
PG0258
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable